Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Hospira's Biosimilar Infliximab Now Substitutable for Remicade in Australia

This article was originally published in Scrip

Executive Summary

The Australian government has announced that Hospira's Inflectra, a biosimilar version of infliximab, is being subsidized under the Pharmaceutical Benefits Scheme as of Dec. 1, 2015, and that pharmacists will be able to substitute it for the reference product, Johnson & Johnson's Remicade.